• Dade Behring (Deerfield, Illinois) reported that it has launched the cardiac-specific CardioPhase hsCRP test on the company's Stratus CS Acute Care diagnostic system. This cardiac-specific high sensitivity C-reactive protein (hsCRP) test has been cleared by the FDA for both risk assessment of future cardiovascular disease and risk stratification of recurrent events. With 2005 revenue of nearly $1.7 billion, Dade Behring says it is the world's largest company dedicated to clinical diagnostics.

• Siemens Medical Solutions (Mountain View, California) reported what it called "the latest in high-end ultrasound imaging — the 4.0 release for its ACUSON Antares ultrasound system, premium edition." The 4.0 edition features shared service cardiology applications in addition to a range of general imaging applications and advanced applications such as 3D/4D and contrast agent imaging. The Antares premium edition is equipped with a high-resolution 19-inch flat panel display mounted on an articulating arm for optimal viewing position. Other ergonomic design features include the extended reach zone concept that places controls and peripheral devices so they are easily accessible, the company said.

• VeraLight (Albuquerque, New Mexico) has received a Notice of Allowance from the U.S. Patent and Trademark Office for the company's patent No. 10,972,173 covering dermal fluorescence technology for its non-invasive screening system, to detect diabetes and pre- diabetes. Slated for market introduction in early 2008, the desktop instrument is designed to detect abnormal concentrations of diabetes-related biological markers found in skin in less than one minute using fluorescent light from an individual's forearm, regardless of skin color. Unlike the fasting plasma glucose test, the device does not require a blood draw or an overnight fast prior to testing. VeraLight developed the first noninvasive diabetes screening system that provides a more accurate and convenient way to detecting Type 2 diabetes and pre-diabetes based on biomarkers in skin.

• Xenomics (New York) has introduced a test for the detection of NPM gene mutations, a recently discovered genetic marker for Acute Myeloid Leukemia (AML). This genetic marker for AML, discovered by Drs. Cristina Mecucci and Brunangelo Falini, collaborators at the Institute of Hematology at the University of Perugia (Perugia, Italy) and licensed by Xenomics, is important for diagnostic accuracy, prognosis, and monitoring of the disease, the company said. Xenomics is a molecular diagnostic company focused on DNA-based tests using transrenal DNA. Xenomics' technology uses urine specimens and is being applied to applications including detection of infectious diseases and tumors, therapeutic monitoring, stem cell transplantation monitoring, and prenatal genetic testing.

No Comments